Fluicell Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Fluicell
Access all reports
Fluicell is a biotech company that specializes in pioneering solutions for bioprinting and single-cell biology. Established in 2012 as a spin-off from Chalmers University of Technology in Gothenburg, Sweden, Fluicell has developed a reputation for its innovative approach to studying and manipulating individual cells with precision. The company's flagship technology, Biopixlar, is a high-resolution 3D bioprinting platform capable of constructing biological tissues at the single-cell level without the need for bioink. This technology is utilized in the development of tissue-based therapies for serious diseases lacking adequate treatments, such as type 1 diabetes, cardiovascular disease, and kidney disease.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
FLUI
Country
🇸🇪 Sweden